1. Home
  2. JLL vs VTRS Comparison

JLL vs VTRS Comparison

Compare JLL & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jones Lang LaSalle Incorporated

JLL

Jones Lang LaSalle Incorporated

HOLD

Current Price

$334.31

Market Cap

14.9B

Sector

Finance

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$11.54

Market Cap

12.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JLL
VTRS
Founded
1997
1961
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.9B
12.0B
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
JLL
VTRS
Price
$334.31
$11.54
Analyst Decision
Buy
Hold
Analyst Count
8
6
Target Price
$342.14
$11.50
AVG Volume (30 Days)
341.0K
7.4M
Earning Date
11-05-2025
11-06-2025
Dividend Yield
N/A
4.19%
EPS Growth
31.91
N/A
EPS
13.05
N/A
Revenue
$25,317,800,000.00
$14,124,400,000.00
Revenue This Year
$11.77
N/A
Revenue Next Year
$7.01
$1.16
P/E Ratio
$25.57
N/A
Revenue Growth
12.51
N/A
52 Week Low
$194.36
$6.85
52 Week High
$340.14
$12.78

Technical Indicators

Market Signals
Indicator
JLL
VTRS
Relative Strength Index (RSI) 61.32 66.35
Support Level $326.69 $10.67
Resistance Level $340.14 $11.83
Average True Range (ATR) 9.00 0.25
MACD 0.42 0.07
Stochastic Oscillator 76.85 75.37

Price Performance

Historical Comparison
JLL
VTRS

About JLL Jones Lang LaSalle Incorporated

Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: